Immatics N.V.
$11.22+4.86%(+$0.52)
TickerSpark Score
58/100
55
Valuation
40
Profitability
10
Growth
84
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMTX research report →
52-Week Range84% of range
Low $4.93
Current $11.22
High $12.41
Companywww.immatics.com
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.
- CEO
- Harpreet Singh
- IPO
- 2018
- Employees
- 554
- HQ
- Tübingen, DE
Price Chart
+107.78% · this period
Valuation
- Market Cap
- $1.50B
- P/E
- -6.03
- P/S
- 34.57
- P/B
- 2.85
- EV/EBITDA
- -4.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 79.32%
- Op Margin
- -571.36%
- Net Margin
- -575.48%
- ROE
- -45.47%
- ROIC
- -43.35%
Growth & Income
- Revenue
- $48.27M · -69.03%
- Net Income
- $-196,447,000 · -1390.89%
- EPS
- $-1.54 · -1200.00%
- Op Income
- $-182,016,000
- FCF YoY
- -0.83%
Performance & Tape
- 52W High
- $12.41
- 52W Low
- $4.93
- 50D MA
- $10.54
- 200D MA
- $9.35
- Beta
- 1.31
- Avg Volume
- 487.05K
Get TickerSpark's AI analysis on IMTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 0 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 18,753 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 255,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 49,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 98,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 90,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 92,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 88,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 160,000 |
| Mar 18, 26 | Reinhardt Carsten Alexander Johannes | other | 40,000 |
Our IMTX Coverage
We haven't published any research on IMTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMTX Report →Similar Companies
INBX+0.46%
Inhibrx Biosciences, Inc.
$110.01
ELVN+4.21%
Enliven Therapeutics, Inc.
$41.86
NKTR+2.83%
Nektar Therapeutics
$69.49
TERN-0.03%
Terns Pharmaceuticals, Inc.
$52.95
TRML+0.00%
Tourmaline Bio, Inc.
$47.98
RLAY+7.87%
Relay Therapeutics, Inc.
$13.02
SNDX+3.98%
Syndax Pharmaceuticals, Inc.
$20.13
ATAI+3.28%
Atai Beckley N.V
$4.09